Infant acute lymphoblastic leukemia (ALL) is frequently characterized by the t(4;11)(q21;q23) cytogenetic abnormality encoding the MLL/AF4 oncogene, increased HOX gene expression and a pro-B/monocytoid phenotype. We have previously established a novel MLL/AF4-positive cell line, B-lineage 3 (BLIN-3), which retains several features of normal B-lineage development (functional Ig gene rearrangement and apoptotic sensitivity to stromal cell withdrawal) not generally observed in infant ALL. We now use microarray analysis to identify patterns of gene expression in BLIN-3 that may modulate MLL/AF4 oncogenesis and contribute to the retention of normal Blineage developmental characteristics. Comparison of 6815 expressed genes in BLIN-3 with published microarray data on leukemic blasts from t(4;11) patients indicated that BLIN-3 was unique in lacking the expression of certain HOX-A cluster genes. These results were validated by RT-PCR showing no expression of HOX A7 or HOX A9 in BLIN-3. A HOX C8 promoter reporter was active in BLIN-3, indicating that lack of HOX gene expression in BLIN-3 was not due to a nonfunctional MLL/AF4. Our results suggest that B-lineage development can proceed in t(4;11) leukemic blasts in the absence of HOX-A gene expression.
Introduction
B cells differentiate from hematopoietic stem cells in a stepwise programmed fashion through a series of developmental checkpoints (reviewed by LeBien 1 ). The pro-B cell is the first readily identifiable B-lineage committed precursor. Pro-B cells exhibit surface expression of the 'stem cell antigen' CD34 and the pan B-cell marker CD19. 2, 3 Most pro-B cells bear DJ rearrangements, although VDJ rearrangements and m-heavy-chain expression can be found in a minority of the CD34 þ CD19 þ compartment. 2, 4 Pre-B cells are defined by cytoplasmic expression of m-heavy chain. 5 These cells are CD19 þ and have lost surface expression of CD34. A subset of pre-B cells express mheavy on the cell surface in association with Vpre and l5. 6 Together with the signaling accessory molecules, Iga and Igb, these form the pre-BCR (see, Burrows et al 7 for review). Survival, proliferation and screening of m-heavy chains have been attributed to pre-BCR signaling, contributing to the hypothesis that it functions to select pre-B cells for subsequent development. These features of B-cell development are highly conserved in mouse and human, and only rarely have these steps been recapitulated in transformed human B-lineage cells. [8] [9] [10] B-lineage ALL is a neoplastic expansion of CD19 þ precursors representing one of the several distinct developmental stages. 1, 11, 12 Infant ALL is a distinct subset characterized by the t(4;11)(q21;q23) cytogenetic abnormality harboring the MLL/AF4 [mixed-lineage leukemia (MLL)/ALL-1 fused gene from chromosome 4 (AF4)] fusion oncogene. MLL/AF4-positive leukemic blasts generally express a 'mixed-lineage' (pro-B/ monocyte) phenotype. 11, 12 While some MLL/AF4-expressing cell lines have exhibited limited acquisition of myeloid lineage characteristics upon supraphysiological treatment with phorbol esters, 13 loss of B-lineage developmental potential is a common feature. This loss of B-lineage developmental potential in MLL/ AF4-positive leukemias is evident not only in failure to differentiate, but also by loss of the normal requirement for BM stromal cells/growth factors for regulated cell growth and loss of apoptotic sensitivity due to growth factor deprivation.
A role for MLL (also called ALL-1 and Hrx) and AF4 in hematopoiesis is not well defined. MLL is a 430 kDa transcription factor highly homologous to the Drosophila trithorax gene (trx). 12 It has a complex structure that includes an AT-hook domain for DNA binding, a methyltransferase region and a SET domain that bears the most similarity to trx. MLL null mice have defects in HOX gene expression and homeotic defects, suggesting a role for MLL in the maintenance of HOX gene expression. 14, 15 A recent report demonstrated that MLL can mediate high levels of HOX C8, HOX A7 and HOX A9 expression through the binding of the MLL SET domain to HOX promoters. 16 However, as truncated MLL does not contain the SET domain, the mechanism(s) of elevated HOX gene expression as a result of MLL fusions remain elusive. Recently published work by Cleary's group suggests that dimerization of MLL fusions may partly explain this apparent paradox.
17 AF4 contains nuclear localization signals and GTP-binding domains, but its function is unknown.
12 AF4-deficient mice exhibit inhibition of T-cell development and a modest alteration in Bcell development. 18 The MLL/AF4 fusion protein preserves the AT-hook and methyltransferase domains of MLL and the GTP binding, and nuclear localization regions of AF4. 12 Although the contribution of MLL/AF4 to leukemogenesis is not precisely defined, MLLlacZ fusions are sufficient to confer oncogenesis in mice, supporting a gain of function role for MLL in neoplastic transformation. 19, 20 Downstream targets of MLL/AF4 are just beginning to be identified, but HOX A7 and HOX A9 have been implicated as targets for dysregulation in MLL-mediated oncogenesis. [21] [22] HOX genes play a pivotal role in hematopoietic lineage commitment and differentiation. HOX A4, HOX A5, HOX A7, and HOX A9 are often considered to be pivitol HOX genes required for MLL trasformation. 12, [14] [15] [16] Furthermore, enforced expression of individual HOX genes can lead to leukemogenesis. 23, 24 In human, there are at least 39 HOX genes organized into four loci located on different chromosomes spanning 100 kb each. 25 Based on position and sequence similarity, HOX genes can be classified into paralog groups that span HOX gene clusters. For example, HOX A1, HOX B1 and HOX D1 form paralog group 1, and HOXA1 shares more sequence homology with these genes than with other HOX A genes such as HOX A2. 26 During development, HOX gene expression occurs in a temporal and spatial fashion, with 3 0 HOX genes (paralog groups 1-4) being expressed earlier in anterior regions followed by more 5 0 HOX genes in posterior regions. 27 Interestingly, there is evidence for a similar 3 0 -5 0 expression pattern in hematopoietic cell differentiation. 23 HOX A and HOX B cluster gene expression is found in CD34 þ subsets and HOX B genes are expressed in peripheral B and T cells. 27 There is also evidence for lineage-specific HOX gene expression, such as the restriction of HOX A10 to myeloid cells. 28 The exact molecular pathways regulated by HOX gene expression in hematopoietic cell growth and differentiation are not fully characterized, but a variety of studies indicate that altered HOX expression can influence differentiation and growth factor responses (Magli et al 23 and references therein). The expression of HOX B8 in a mouse myeloid cell line blocks IL-6-induced differentiation. 29 HOX B7 is expressed in human bone marrow upon GM-CSF stimulation, and reduced HOX B7 expression inhibits the formation of GM-CSF-induced colony formation. 30 HOX A9 À/À mice exhibit a reduction in peripheral lymphocytes, myeloid progenitors and pre-B cells. 31 These mice also have a profound reduction in GM-CSF responses. The overexpression of HOX A9 murine bone marrow stem cells results in stem cell expansion and a reduced in vitro IL-7 proliferative response of B-cell precursors. 32 Interestingly, these mice did not exhibit lymphoid lineage transformation, and B-lineage bone marrow subcompartments were relatively normal.
We described a novel t(4;11) ALL cell line termed B-lineage 3 (BLIN-3), which expresses the MLL/AF4 oncoprotein and exhibits a normal pro-B cell to pre-B cell developmental program, stromal cell dependency, an IL-7 response and an intact apoptotic program upon growth factor withdrawal. 9 These biological characteristics of BLIN-3 suggested that the expression of MLL/AF4 alone does not perturb the normal developmental program of human B-lineage cells.
In order to identify genes that may cooperate with MLL/AF4 to modulate B-lineage leukemogenesis, we used microarray analysis to compare patterns of gene expression in BLIN-3 to freshly isolated t(4;11) leukemic blasts. 21 Interestingly, BLIN-3 completely lacked the expression of HOX A9, HOX A7, HOX A5 and HOX A4, suggesting that the expression of these genes may be required to abrogate B-cell development in the presence of the MLL/AF4 oncoprotein.
Materials and methods
Cells lines and tissue culture: BLIN-3 cells (t(4;11) infant-ALL) were cultured on stromal cell layers in XVIVO-10 medium supplemented with IL-7. 9 RS4;11 (t(4;11) infant-ALL), 13 SEM K2 (t(4;11) infant ALL), 33 U937 (AML), NALM-6 (pre-B ALL) and BLIN-1 (pre-B ALL) 8 were maintained in RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum. An original cyropreservation of BLIN-3 (OR BLIN-3) that had been cultured for 2 weeks, but never passaged, was thawed rapidly in a 371C water bath, washed twice with media and then used for subsequent RT-PCR analysis.
Microarray gene chip analysis
Total RNA, double-stranded cDNA and labeled RNA were prepared from four independent cultures of m þ BLIN-3, using Affymetrix (Affymetrix, Inc., Santa Clara, CA, USA) recommended protocols. Each BLIN-3-labeled RNA sample was probed with a U95A Total Named Gene Microarray (Affymetrix, Inc.). Microarrays were hybridized and scanned at the University of Minnesota Biomedical Genomics Center. Data were analyzed using MicroArray Suite 5.0 and DataMining Tool (Affymetrix, Inc.). In order to permit relative comparisons across multiple chips, gene expression values for each chip data set (n.CHP files) were scaled to the same expression value range.
Genes with an expression P-value o0.05 were collected from each of four BLIN-3 arrays and each of eight t(4;11) patient arrays 21 (www.genome.wi.mit.edu/cgi-bin/cancer/datasets.cgi). The Mann-Whitney test was performed to determine if a given gene changed in expression between BLIN-3 samples and t(4;11) patient samples. A Mann-Whitney P-value o0.05 indicated the expression change. The average signal value for each gene was calculated for the BLIN-3 samples and the t(4;11) patient samples. For each gene, log 2 (fold change) was calculated as log 2 ((average BLIN-3 signal)/(average t(4;11) signal)). Data were sorted by log 2 (fold change) and by Mann-Whitney change direction (ie up or down). This BLIN-3 data set and the unprocessed BLIN-3 array data are available at www.ecu.edu/ microbiology/BLIN3_array.htm.
RT-PCR and Southern blotting was performed as described previously. 9 PCR primer pairs for HOX A9, HOX A7 and Meis1 genes have been published. 34, 35 Luciferase assays 
Results

Microarray gene chip analysis
Four independently harvested cultures of m þ BLIN-3 cells were analyzed on Affymetrix U95A chips. These data were compared with published array data on eight t(4;11) patient samples. 21 While such a comparison between a cell line and patient specimens may introduce unexpected variability due to differences in sample selection or processing, the salient features of this analysis were consistent with known biological and developmental features of BLIN-3 (see below). There were 6815 genes expressed in BLIN-3, 5029 of which were expressed at levels similar to that in t(4;11) patient samples. A total of 706 genes showed a two-fold or greater increase and 312 genes showed a two-fold or greater decrease in BLIN-3 compared to t(4;11) patient samples. Of the 6815 BLIN-3 expressed genes, 768 genes were expressed in at least one of the four BLIN-3 replicates but not in any t(4;11) sample. Of these 768, 112 genes were expressed in all four BLIN-3 replicates, but not in any of the t(4;11) patient samples.
17 genes (not among the 6815 BLIN-3 expressed genes) were expressed by all of the t(4;11) patient samples and none of the BLIN-3 replicates. Eight were cDNAs of unknown identity. The remaining nine were CD44 (L05424), AHNAK (M80899), lipocortin (X05908), TGF-b (M38449), NF-IL6-b (M83667), HOX A7 (AJ005814), EDN (X55988), motilin (X15393) and BST-1 (D21878).
BLIN-3 cells express B-lineage-associated genes
BLIN-3 cells exhibited increased or unique expression of several genes associated with B-lineage development, consistent with our previous studies demonstrating that BLIN-3 is capable of undergoing pro-B to pre-B cell development. 9 Notable was an eight-fold increase in 14.1 (l5) expression and a four-fold increase in m-heavy-chain transcripts ( Table 1 ). The tyrosine kinase BTK was also increased in BLIN-3. The expression of myeloid lineage-associated genes CD44, Mir-10, MNDA as well as TGF-b was found only in t(4;11) patient samples. No difference between Flt3 expression was observed between BLIN-3 samples and t(4;11) patient samples.
BLIN-3 cells lack HOX A9, HOX A7, HOX A5 and HOX A4 gene expression
MLL-fusions are associated with an increase in HOX gene expression. 21, 22 HOX A9, HOX A7, HOX A5 and HOX A4 were not expressed in BLIN-3, but were expressed in t(4;11) patient samples ( Table 1) . HOX A7 was expressed in eight of eight t(4;11) patient samples, HOX A9 in six of eight, HOX A5 in three of eight and HOX A4 in one of eight. HOX A1, which is not targeted by MLL, 16, 36 exhibited no difference in expression between BLIN-3 and t(4;11) samples. HOX C8 expression was not detected in BLIN-3 or t(4;11) samples.
RT-PCR confirmed that HOX A7 and HOX A9 were not detected in BLIN-3 ( Figure 1, left panel) , but were readily detected in the well-characterized t(4;11) cell line RS4;11 and the U937 monocytoid cell line. Importantly, HOX A9 and HOX A7 were not detected in m À BLIN-3 cells (pro-B) or in m þ BLIN-3 cells (pre-B), indicating that HOX A9 and HOX A7 expression was not being lost as a function of B-cell differentiation. Moreover, HOX A7 and HOX A9 were not expressed in OR BLIN-3, an original cryopreservation of the BLIN-3 sample (Figure 1, right panel) . Thus, it is unlikely that HOX gene expression was lost as a result of prolonged culture with IL-7 and stromal cells. The OR BLIN-3 cells expressed the MLL/AF4 fusion gene (Figure 1) . HOX A7 and HOX A9 were also not detected in BLIN-1, a pre-B ALL cell line lacking the t(4;11) abnormality that undergoes pre-B to immature B-cell differentiation. 8 Transformation involving HOX A9 is enhanced by cooperation with Meis1-and Pbx-family members.
36-40 BLIN-3 samples exhibited unique or increased expression of Pbx2 and Pbx3, respectively ( Table 1 ). The expression of Meis1 was similar between BLIN-3 and t(4;11) samples, and the expression was confirmed via RT-PCR (Figure 1 ). Lineage-associated and HOX gene expression in BLIN-3 as determined from U95A Affymetrix arrays. Accession number and fold change (parentheses) as compared with the expression in t(4;11) patient samples 21 are indicated.
BLIN-3 MLL/AF4 oncoprotein can activate the HOX C8 promoter
MLL fusions have been shown to activate HOX C8 and HOX A9 promoters. 16 To test if a HOX promoter would be transcriptionally active in BLIN-3, we transfected m þ BLIN-3 cells with a HOX C8 promoter luciferase (HOX C8-Luc) reporter, 16 and compared HOX C8 promoter activity in BLIN-3 to that in the t(4;11) cell lines SEMK2 and RS4;11. In these experiments, HOX C8-Luc is a surrogate for MLL/AF4 oncoprotein activity. As shown in Figure 2 , the HOX C8 reporter was highly active in each of the t(4;11) cell lines including BLIN-3, but was minimally active in NALM-6 or U937 that do not bear the t(4;11) abnormality. These data provide evidence that the BLIN-3 MLL/AF4 oncoprotein is functional in terms of transcriptional activation of HOX promoters.
Discussion
We recently described the characterization of a t(4;11) cell line, BLIN-3, which has retained stromal cell/growth factor dependency and apoptotic responsiveness similar to that of normal pro-B and pre-B cells, despite the expression of the MLL/AF4 oncoprotein. 9 Moreover, we demonstrated that BLIN-3 would phenotypically and functionally differentiate from the pro-B cell to the pre-B cell stage as accessed by: stochastic DJ to V(D)J rearrangement, subsequent surface expression of the pre-BCR (m-cLC), and a proliferative response to pre-BCR crosslinking. 9 Importantly, both m À BLIN-3 (pro-B) and m þ BLIN-3 (pre-B) expressed MLL/AF4 message and protein similar to that of other well-characterized t(4;11) cell lines that exhibit a more classical t(4;11) phenotype. 9 The aforementioned data suggested that MLL/AF4 expression alone may not be sufficient to confer apoptotic resistance to growth factor withdrawal and to arrest B-lineage development. In this study, we used microarray technology to screen gene expression in m þ BLIN-3 cells and compared that gene expression to previously published array data 21 on eight t(4;11) patient samples. Our array study revealed that four independent analyses of BLIN-3 lacked the expression of HOX A4, HOX A5, HOX A7 and HOX A9 ( Table 1) . Lack of HOX A7 and HOX A9 expression in BLIN-3 was verified by RT-PCR (Figure 1 ). In contrast, these genes were expressed in other t(4;11) cell lines ( Figure 1) .
MLL is a member of the trx family of genes that in Drosophila are positive regulators of HOX gene expression. 12 In the mouse, MLL has been shown to augment the expression of HOX A7, HOX A9 and HOX C8, and MLL is necessary to maintain HOX gene expression. 14, 15, 37 Increased expression of HOX A5, HOX A7 and HOX A9 has been documented in MLL-associated leukemias, 21, 22, 41 and enforced expression of individual HOX genes has been shown to transform primary hematopoietic stem cells. 23, 24 Although it has been suggested through microarray analysis of MLL-positive T-and B-lineage leukemic patient samples that overexpression of HOX is a key step in oncogenesis, 41 a direct requirement for HOX gene expression in MLLmediated transformation or an altered leukemic phenotype in MLL-positive leukemia in the absence of HOX gene expression has yet to be demonstrated. In this study, we present evidence that lack of HOX gene expression may influence the biological properties of an MLL-positive leukemia.
Our PCR analysis did not detect HOX A7 or HOX A9 in m À BLIN-3 or m þ BLIN-3, confirming the array data and suggesting that HOX gene expression was not being lost as a function of Bcell development (Figure 1) . Moreover, we found that HOX A7 and HOX A9 were not expressed in an original sample of BLIN-3 (OR BLIN-3) that had never been passaged, although this sample expressed the MLL/AF4 fusion gene (Figure 1) . Thus, HOX gene expression was not lost in BLIN-3 as a result of prolonged culture. Although other unidentified factors may contribute to the unique biological properties of BLIN-3, the absence of HOX gene expression is unusual and novel for MLL/ AF4-expressing cells, as HOX A4, HOX A5, HOX A7 and HOX A9 upregulation is well-documented leukemic t(4;11) cells.
Importantly, we demonstrated that the BLIN-3 MLL/AF4 oncoprotein was functionally capable of transactivating the HOX C8 promoter (Figure 2 ) similar to other t(4;11) cell lines, such as RS4;11 and SEMK2 that exhibit arrested B-cell development, apoptotic resistance and express HOX A7 and HOX A9 (Figure 1 and 2) . It is not clear why HOX genes that are normally overexpressed in the presence of truncated MLL are not expressed in BLIN-3, although it is possible that BLIN-3 may bear cytogenetically silent mutation(s) in the HOX A cluster that prevent expression of these genes. HOX A genes are not normally expressed in B-lineage committed cells, 23, 24 thus an alternative explanation may be that BLIN-3 has not retained enough of a monocytoid genetic program to permit the expression of the endogenous HOX gene locus. Comparison of HOX C8-Luc activity in BLIN-3 to that of the HOX A9-expressing t(4;11) cell lines RS4;11 and SEMK2 provides an indirect measure of the functional ability of the BLIN-3 MLL/AF4 fusion to activate a HOX promoter known to be upregulated in MLL-positive leukemia. BLIN-3 expresses a functional MLL/AF4 oncoprotein, and its lack of HOX gene expression provides evidence that MLL/AF4 dysregulated HOX gene expression is a necessary step in altering B-cell development in t(4;11) leukemogenesis.
Our data suggest a model (Figure 3 ) of leukemogenesis in which HOX A9 and/or HOX A7 gene expression enhance MLL/ AF4 oncogenesis. In conventional t(4;11), MLL/AF4 leads to transformation, consistent with studies demonstrating that truncated MLL is sufficient for transformation. 19, 20 The presence of MLL/AF4 also promotes aberrant expression of HOX A7 and HOX A9. These interact with Meis1 and Pbx 37, 40 to augment MLL oncogenesis, by potentially enhancing apoptotic resistance, growth factor independent growth and loss of developmental potential. In the BLIN-3 t(4;11) cell line, truncated MLL leads to transformation/immortalization. However, lack of HOX A7 and HOX A9 expression blocks Hox/Meis/Pbx-mediated enhancement of MLL oncogenesis, resulting in the retention of normal B-developmental features. Interestingly, HOX A5 and HOX A10 have been shown to interact with FKHR regulating IGFBP-1 expression, 42, 43 providing a potential pathway leading from altered HOX gene expression to loss of stromal cell/growth factor dependency in MLL leukemia. As recent studies have indicated that mechanisms of HOX gene regulation differ between wild-type MLL and truncated MLL, 16 BLIN-3 is a useful model for examining the regulation and potential requirement for HOX gene expression in MLL-mediated oncogenesis during human B-cell development.
